key: cord-1020817-e5o2hnfn
authors: Mousaad Elemam, Noha; Hannawi, Haifa; Bin Naeem, Kashif; Hannawi, Suad
title: A single centered study reveals association between liver injury and COVID-19 infection
date: 2021-06-25
journal: Saudi J Biol Sci
DOI: 10.1016/j.sjbs.2021.06.064
sha: 9a9ce67a5b01e603d02ef4e9633eeab1224550f3
doc_id: 1020817
cord_uid: e5o2hnfn

Background and aim Despite the fact that it has been over a year with the pandemic COVID-19 infection, ongoing research and analysis reveal many complications and comorbidities associated with COVID-19. In this study, we aimed at investigating the clinical and laboratory assessments in COVID-19 patients with and without liver injury. Methods: Symptomatic 541 COVID-19 positive patients, who were admitted to Al Kuwait Hospital, Dubai, United Arab Emirates (UAE), were recruited in this study. Their data was collected retrospectively, including demographic data, blood tests, symptoms, radiographical assessments, and clinical outcomes of COVID-19. Results: Around 19% of the recruited COVID-19 patients displayed signs of acute liver injury. Also, there was an increase in the percentage of critical, ICU-admitted and mortality rates in COVID-19 cases with liver injury, as well as a higher percentage of septic shock and acute respiratory distress syndrome (ARDS). COVID-19 patients with liver injury had more pronounced bilateral consolidation, lymphopenia and neutrophilia. Additionally, these patients had higher levels of CRP, LDH, procalcitonin, ferritin and D dimer levels. Finally, there was a higher percentage of patients taking various COVID-19 therapies in the COVID-19 patients with liver injury group. Conclusion: COVID-19 patients with acute liver injury are at a higher risk for serious outcomes including death.

It has been more than a year since the discovery of the SARS-CoV-2 virus, that still remains a global pandemic till now. COVID-19 infection caused by SARS-CoV-2 was reported to be associated with various symptoms according to the stage, that could start off with fever, sore throat, loss of taste and smell, and could end in pneumonia and even acute respiratory distress syndrome (ARDS). However, COVID-19 complications were associated with multiple comorbidities including diabetes, hypertension as well as cardiac, gastrointestinal and renal dysfunction (Rismanbaf, A. and S. Zarei, 2020, Wang, T. et al., 2020) .

Although the lung is the main site of SARS-CoV-2 infection, previous reports indicated that around 10% of COVID-19 patients had liver damage as the levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were abnormal (Garrido, I. et al., 2020 , Huang, C. et al., 2020 , Rismanbaf, A. and S. Zarei, 2020 . More, severe and ICU-admitted COVID-19 patients exhibited liver dysfunction, as observed by elevated liver enzymes (Bangash, M.N. et al., 2020 , Guan, W.-j. et al., 2020 , Wang, D. et al., 2020 , Zhang, C., L. Shi et al., 2020 . Previous liver biopsies obtained from COVID-19 patients showed leukocyte infiltration into the lobular and portal sites coupled with hepatocyte degeneration and focal necrosis, as well as microvascular steatosis, indicating liver injury upon infection with SARS-CoV-2 .

Various possible theories were suggested to be behind the liver dysfunction seen in COVID-19 patients (Zhang, C., L. Shi et al., 2020) . One could be the inflammation caused by the immune dysfunction including the cytokine storm . A second possibility could be direct viral entry through the known SARS-CoV-2 entry receptor angiotensin-2 converting enzyme (ACE2) (Wang, D., B. Hu et al., 2020) , that is present on cholangiocytes in liver tissues, thus causing bile duct dysfunction (Chai, X. et al., 2020) . Another possible proposition is the hepatotoxicity caused by drugs used for COVID-19 treatment (Cao, J., X. Cai et al., 2020) . These drugs include the antiviral drugs oseltamivir, ritonavir/lopinavir, and remdesivir, as well as the anti-inflammatory chloroquine and hydroxychloroquine, all of which are metabolized in the liver and would cause hepatotoxicity (Yang, R.-X. et al., 2020 . Also, pneumonia and critical symptoms of COVID-19 could be a contributing factor in liver damage (Chand, N. and A.J. Sanyal, 2007, Ghoda, A. and M. Ghoda, 2020) . Finally, some studies suggested that COVID-19 might trigger further liver damage in patients with pre-existing liver diseases (Ali, N., 2020) .

In this study, we aimed at investigating the effect of liver dysfunction on the laboratory blood tests, symptoms, clinical outcomes and mortality rate in COVID-19 patients that were admitted to the first hospital that had been devoted to COVID-19 cases.

A total of symptomatic 541 COVID-19 positive patients, who were admitted to Al Kuwait Hospital, Dubai, United Arab Emirates (UAE), were recruited in this study and their data was collected retrospectively. Ethical approval for this study was obtained from Ministry of Health and Prevention Research Ethics Committee (MOHAP/DXB-REC/MMM/NO.44/2020) and conforms to the provisions of the Declaration of Helsinki.

The clinical data included age, sex, medical history of other organ dysfunctions including acute cardiac injury, acute kidney injury, and ARDS. Also, the duration of illness was recorded.

Symptoms associated with COVID-19 were documented including fever, myalgias, fatigue, anorexia, headache, confusion, rhinorrhea, shortness of breath, sore throat, cough, sputum production, hemoptysis, nausea, vomiting, and diarrhea. Blood tests including white cell count (WCC), platelets, neutrophil count, lymphocyte count, hemoglobin (Hb), HbA1c, ferritin, lactate dehydrogenase (LDH), C-reactive protein (CRP), procalcitonin, troponin and coagulation tests (D-dimer and the international normalized ratio; INR).

The data of liver function tests including albumin level, alanine aminotransferase (ALT), aspartate aminotransaminase (AST), serum bilirubin and alkaline phosphatase level (ALP) were collected. All the liver function tests were performed at the time of admission to the hospital. Liver injury was defined by the presence of high ALT and/or high AST by more than five times the upper limit of normal reference range.

Clinical outcomes of COVID-19 had been reported (intensive care unit admission; ICU, need for mechanical ventilation, acidosis, septic shock and death). COVID-19 patients were classified based on the following criteria, 1-mild to moderate; no pneumonia or mild pneumonia, 2-severe; presence of dyspnea, respiratory rate ≥ 30/min, blood oxygen saturation ≤ 93%, ratio of partial pressure of arterial oxygen (PaO 2 ) to fraction of inspired oxygen (FiO 2 ) < 300, and lung infiltrates > 50% within 24-48 hours, and 3-critical; respiratory failure, septic shock, or multiorgan dysfunction/failure. Besides, radiographical assessment using chest X-ray and computed tomography (CT) tests was performed for the investigated individuals. The treatment regimens used for management of COVID-19 therapy included hydroxychloroquine (HCQ), antivirals such as lopinavir-ritonavir and favipiravir, antibodies, steroids, interferon, anti-fungal agents and IL-6 receptor blocker Tocilizumab.

SARS-CoV-2 infected individuals suffering from acute liver injury were compared to those without liver injury. The values represent mean ± SEM for the continuous variables, or percentage relative to the total number of patients in each group for the categorical variables. Statistical analysis was performed using GraphPad Prism 6 software (GraphPad Software, San Diego, CA, USA). Student's t-test was used to assess the differences between the groups for the continuous variables, while Chi-square test was used for the categorical variables. P value < 0.05 was considered statistically significant.

All the collected data along with the respective p values are listed in table 1.

In order to categorize COVID-19 patients into 2 groups with and without liver dysfunction, the levels of liver enzymes, bilirubin and albumin were compared. As seen in figure 1A-C, elevated levels of ALT, AST and ALP were observed in those in the liver impairment COVID-19 group compared to those without (p<0.0001, p<0.0001 and p=0.0025, respectively). Furthermore, bilirubin levels were elevated in COVID-19 patients with liver dysfunction (p=0.0003), while hypoalbuminemia was found in those patients (p<0.0001) as shown in figure 1D and 1E.

After categorizing COVID-19 patients into two groups based on liver dysfunction, it was worth investigating if these patients had other organ dysfunctions such as cardiac injury.

Indeed, COVID-19 patients with liver impairment, exhibited more cardiac injury (p< 0.0001), which was further supported by an increase in their troponin levels (p=0.0040, figure 2A-B).

It seems that liver dysfunction might be a contributing factor that is associated with severity and mortality of COVID-19 infection. As illustrated in figure 3A -B, there was a decline in the percentage of mild-moderate patients with acute liver injury while there was a concomitant increase in the percentage of critical and ICU-admitted COVID-19 patients (figure 3C-D, p< 0.0001). It was quite interesting that along with liver damage, it was noted that there was a higher percentage of patients with septic shock (figure 3E), acidosis (figure 3F), ventilated individuals (figure 3G), and ARDS (figure 3H, p< 0.0001 for all).

It was revealed that a higher percentage of COVID-19 patients had bilateral consolidation and bilateral peripheral ground opacities in their chest X-ray and CT scans ( 

COVID-19 was associated with an increase in the white cell count (WCC) as well as lymphopenia and neutrophilia. As shown in figure 5A-C, this was further highlighted in patients with liver damage as they had a higher white cell count (p=0.002) and exhibited much more significant lymphopenia and neutrophilia (p<0.0001 for both). Additionally, those patients had higher levels of inflammation markers associated with COVID-19

including CRP (figure 5D, p<0.0001), LDH (figure 5E, p<0.0001), procalcitonin (figure 5F, p<0.0001), ferritin (figure 5G, p<0.0001) and D dimer levels (figure 5H, p= 0.0002). Similar to D-dimer levels, other coagulopathy related factors were different in COVID-19 patients with liver damage as observed in the decrease in the INR levels (figure 5I, p=0.0002) in liver-impaired COVID-19 patients.

It was crucial to investigate if there was a difference in the drugs used for therapy of COVID-19 patients with and without liver injury. Different therapies included tocilizumab, favipiravir, antifungal agents, interferon, steroids and IV antibodies. As shown in figure   6A -C, there was a higher percentage of patients taking tocilizumab, steroid and IV antibodies in the COVID-19 patients with liver injury group (p<0.0001). Furthermore, a higher percentage of COVID-19 patients with liver injury took interferon (p=0.0172), favipiravir (p=0.0017), and antifungal agents (p=0.0032).

The global pandemic COVID-19 caused by SARS-CoV-2 virus still remains a mystery to many researchers around the world. Despite the fact that it primarily affects the pulmonary system, several studies reported that COVID-19 infection affects other organs including renal, cardiovascular, gastrointestinal and hepatic systems (Guan, W.-j., Z.-y. Ni et al., 2020 , Huang, C., Y. Wang et al., 2020 , Wang, D., B. Hu et al., 2020 , Yang, X., Y. Yu et al., 2020 . In this study, out of the 541 recruited COVD- Interestingly, we found that COVID-19 patients with liver injury had milder COVID-19 symptoms such as headache, fatigue, and sore throat. While there was a higher percentage of COVID-19 patients had fever, cough and shortness of breath (SOB). Again, this could be due to the finding that more critical and ICU admitted patients fall in the liver dysfunction group. This was further supported by the blood test findings with more Zheng et al., 2020) , and highlights that care should be taken in the therapeutic use of various types of medications, doses, and durations of medicines in order to reduce the chance of drug-induced liver injury, as well as maintain liver function and protection. This supports previous studies that reported that acute liver injury and hepatotoxicity observed in COVID-19 could be due to either the drugs or it might be a synergistic effect between the virus and the used drugs. Whether patients with a background of liver impairment prior to COVID-19 acquisition are more likely to contract the viral infection and to exhibit more liver impairment is a question that needs to be further investigated.

COVID-19 infection could lead to multiple organ dysfunctions, that should be monitored and deeply investigated during and post-COVID-19 infection. In this study, we reported that COVID-19 patients presenting with acute liver injury are at a higher risk for serious outcomes including death. However, this study has some limitations where pre-existing elements of liver impairment cannot be ruled out. This could be further investigated in future studies. Also, it would be interesting to investigate if elderly patients are at a higher risk of developing impaired liver functions. Future work would be needed to understand the short-and long-term effects of SARS-CoV-2 and used therapeutics on the various systems of the human body.

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. 

while there was a decrease in the levels of (I) INR.

favipiravir, and (F) antifungal drugs was found in the liver dysfunction group. 

Liver Injury in COVID-19: Caution and Management

Specific ACE2 Expression in Cholangiocytes May Cause Liver Damage After 2019-nCoV Infection. bioRxiv

Sepsis-induced cholestasis

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

Clinical Features of COVID-19-Related Liver Damage. medRxiv

Review article: COVID-19 and liver disease-what we know on 1st

Liver Injury in COVID-19 Infection: A Systematic Review

Zhu and N.-s. Zhong 2020. Clinical Characteristics of Coronavirus Disease 2019 in China

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Acute Liver Injury in COVID-19: Prevalence and Association with Clinical Outcomes in a Large U

Liver and Kidney Injuries in COVID-19 and Their Effects on Drug Therapy; a Letter to Editor

COVID-19 and liver disease

Novel Coronavirus-Infected Pneumonia in Wuhan, China

Comorbidities and multi-organ injuries in the treatment of COVID-19

Pathological findings of COVID-19 associated with acute respiratory distress syndrome

Etiology and management of liver injury in patients with COVID-19

Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study

Liver injury in COVID-19: management and challenges

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Manuscript title:The authors whose names are listed immediately below certify that they have NO affi liations with or involvement in any organization or entity with any fi nancial interest (such as honoraria; educational grants; participation in speakers' bureaus; membership, employment, consultancies, stock ownership, or other equity interest; and expert testimony or patent-licensing arrangements), or non-fi nancial interest (such as personal or professional relationships, affi liations, knowledge or beliefs) in the subject matter or materials discussed in this manuscript.Author names:The authors whose names are listed immediately below report the following details of affi liation or involvement in an organization or entity with a fi nancial or non-fi nancial interest in the subject matter or materials discussed in this manuscript. Please specify the nature of the confl ict on a separate sheet of paper if the space below is inadequate. This statement is signed by all the authors to indicate agreement that the above information is true and correct (a photocopy of this form may be used if there are more than 10 authors):